EpiPen maker racking up taxpayer dollars

By Robert King

Published October 6, 2016 6:30pm ET

Add Washington Examiner on Google

EpiPen maker racking up taxpayer dollars — Mylan has drawn bipartisan anger for raising the price of the EpiPen by 400 percent since acquiring it in 2007. The price tag now runs $600 for a two-pack of the life-saving drug. (AP Photo/Pablo Martinez Monsivais) | Pablo Martinez Monsivais

The maker of the allergy drug EpiPen racked up an increasing amount of money from taxpayer-funded government programs over the past five years, Sen. Chuck Grassley says.

The share of Mylan’s revenue from government programs such as Medicaid and Medicare rose 30 percentage points from 23.3 percent in 2011 to 53.4 percent in 2015, the Iowa Republican’s office found.

Print subscriber? Click here to login/register your account

Digital subscriber? Click here to login/register your account.

Full midterm coverage.Deeper analysis.

Get unlimited access to Washington Examiner's reporting, expert analysis, and coverage of the midterm elections.

Get Unlimited Access

Cancel anytime.

Tag:

Chuck Grassley Epipen Medicare and Medicaid Minusextra Pharmaceutical Industry Robert King